dc.contributor.author | Saez-Comet, Luis | |
dc.contributor.author | Cervello, Gonzalo Salvador | |
dc.contributor.author | Sebastiani, Gian Domenico | |
dc.contributor.author | Squatrito, Danilo | |
dc.contributor.author | Szucs, Gabriella | |
dc.contributor.author | Caminal-Montero, Luis | |
dc.contributor.author | Castro, Antoni | |
dc.contributor.author | Colodro Ruiz, Agustin | |
dc.contributor.author | Doria, Andrea | |
dc.contributor.author | Domer, Thomas | |
dc.contributor.author | Gonzalez-Echavarri, Cristina | |
dc.contributor.author | Gremese, Elisa | |
dc.contributor.author | Houssiau, Frederic A. | |
dc.contributor.author | Huizinga, Tom | |
dc.contributor.author | Isenberg, David | |
dc.contributor.author | Luliano, Annamaria | |
dc.contributor.author | Jacobsen, Soren | |
dc.contributor.author | Jimenez-Alonso, Juan | |
dc.contributor.author | Kovacs, Laszlo | |
dc.contributor.author | Mariette, Xavier | |
dc.contributor.author | Mosca, Marta | |
dc.contributor.author | Nived, Ola | |
dc.contributor.author | Oristrell, Joaquim | |
dc.contributor.author | Ramos-Casals, Manuel | |
dc.contributor.author | Rascon, Javier | |
dc.contributor.author | Ruiz-Irastorza, Guillermo | |
dc.contributor.author | Saez-Comet, Luis | |
dc.contributor.author | Salvador Cervello, Gonzalo | |
dc.contributor.author | Ruiz-Irastorza, Guillermo | |
dc.contributor.author | Voskuyl, Alexandre | |
dc.contributor.author | van Vollenhoven, Ronald | |
dc.contributor.author | Inana, Murat | |
dc.contributor.author | Ryden-Aulin, Monica | |
dc.contributor.author | Boumpas, Dimitrios | |
dc.contributor.author | Bultink, Irene | |
dc.contributor.author | Rubio, Jose Luis Callejas | |
dc.date.accessioned | 2021-03-03T09:03:30Z | |
dc.date.available | 2021-03-03T09:03:30Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Ryden-Aulin M., Boumpas D., Bultink I., Rubio J. L. C. , Caminal-Montero L., Castro A., Colodro Ruiz A., Doria A., Domer T., Gonzalez-Echavarri C., et al., "Off-label use of rituximab for systemic lupus erythematosus in Europe", LUPUS SCIENCE & MEDICINE, cilt.3, sa.1, 2016 | |
dc.identifier.other | av_1af7a189-0c8e-4413-a092-5dead74079ba | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/23419 | |
dc.identifier.uri | https://doi.org/10.1136/lupus-2016-000163 | |
dc.description.abstract | Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. | |
dc.language.iso | eng | |
dc.subject | İmmünoloji ve Romatoloji | |
dc.subject | ROMATOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.title | Off-label use of rituximab for systemic lupus erythematosus in Europe | |
dc.type | Makale | |
dc.relation.journal | LUPUS SCIENCE & MEDICINE | |
dc.contributor.department | Karolinska Institutet (Karolinska Institute) , , | |
dc.identifier.volume | 3 | |
dc.identifier.issue | 1 | |
dc.contributor.firstauthorID | 229801 | |